Cookson Peirce & Co. Inc. Takes Position in 10x Genomics $TXG

Cookson Peirce & Co. Inc. bought a new stake in 10x Genomics (NASDAQ:TXG) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 25,000 shares of the company’s stock, valued at approximately $290,000.

Several other large investors also recently made changes to their positions in the company. Blue Trust Inc. grew its stake in shares of 10x Genomics by 48.1% in the 2nd quarter. Blue Trust Inc. now owns 4,894 shares of the company’s stock valued at $57,000 after buying an additional 1,590 shares during the period. GAMMA Investing LLC grew its stake in shares of 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after buying an additional 1,614 shares during the period. Xponance Inc. grew its stake in shares of 10x Genomics by 17.4% in the 1st quarter. Xponance Inc. now owns 12,010 shares of the company’s stock valued at $105,000 after buying an additional 1,778 shares during the period. AlphaQuest LLC grew its stake in shares of 10x Genomics by 8.3% in the 1st quarter. AlphaQuest LLC now owns 29,459 shares of the company’s stock valued at $257,000 after buying an additional 2,258 shares during the period. Finally, Signaturefd LLC grew its stake in shares of 10x Genomics by 134.3% in the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock valued at $37,000 after buying an additional 2,409 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Stock Up 9.0%

10x Genomics stock opened at $13.36 on Friday. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $18.21. The company’s 50 day moving average price is $12.87 and its two-hundred day moving average price is $11.29. The stock has a market cap of $1.66 billion, a P/E ratio of -19.09 and a beta of 2.05.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million for the quarter, compared to analysts’ expectations of $139.36 million. During the same quarter last year, the firm earned ($0.32) EPS. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities analysts anticipate that 10x Genomics will post -1.43 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on TXG shares. UBS Group lifted their price target on 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Morgan Stanley cut their price target on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday, August 12th. Bank of America lifted their price target on 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday, June 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research note on Tuesday, October 14th. Finally, Barclays reiterated an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and a consensus price target of $13.65.

Insiders Place Their Bets

In related news, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the sale, the insider owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. This trade represents a 6.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,149 shares of company stock valued at $539,865 in the last 90 days. 9.39% of the stock is currently owned by corporate insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.